CoChat

Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data

Open access
Zhao, Zhe, Tang, Yan, Hu, Yang, Zhu, Huijuan, Chen, Xiaoguang, Zhao, Bin · 2021 · Annals of Translational Medicine

The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.

Abstract

Background: Recent evidence has emerged concerning hypoglycemia following the application of glucagon-like peptide-1 receptor agonists (GLP-1RAs). Nevertheless, few real-world investigations have been performed to determine the clinical characteristics, onset, and outcomes of hypoglycemia associated with different GLP-1RAs. This study aimed to compare and assess the relationship between various GLP-1RAs and hypoglycemia in a large population based on updated data from the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Bayesian and disproportionality analyses were applied to data mining in order to investigate suspected cases of hypoglycemia following various GLP-1RAs using the FAERS data between January 2004 and September 2020. We also evaluated the onset time, fatality risks, and hospitalization proportions of GLP-1RA-related hypoglycemia. Results: We identified 1,164 GLP-1RA-associated hypoglycemia cases, which seemed to affect more middle-aged patients than elderly ones. Also, females were more affected than males. Lixisenatide demonstrated a stronger association with hypoglycemia compared to other GLP-1RAs, according to the highest reporting odds ratio (ROR) (28.03, 95% confidence interval =15.92, 49.32), empirical Bayes geometric mean [26.00, 95% confidence interval (CI): 16.20], and proportional reporting ratio (PRR) (26.01, χ2=313.37). The median time to hypoglycemia onset was 5 days (interquartile range, 0–67.75 days) following GLP-1RA treatment. In general, GLP-1RA-associated hypoglycemia resulted in fatality and hospitalization proportions of 3.53% and 56.08%, respectively. Conclusions: By analyzing the FAERS data, we outlined the association between hypoglycemia and different GLP-1RAs in greater detail in terms of clinical features, onset, and outcomes. Among all six GLP-1RAs, lixisenatide demonstrated the strongest association with hypoglycemia while no relationship between albiglutide and hypoglycemia was observed. Attention should be given to GLP-1RAs when used in patients with high risks of hypoglycemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/atm-21-4162

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Selection process of cases of GLP-1RA-associated hypoglycemia from the FAERS database. DEMO, demographic and administrative information; DRUG, drug information; FAERS, Food and Drug Administration’s Adverse Event Reporting System; GLP-1RA, glucagon-like peptide-1 receptor agonist; REAC, adverse event.
Figure 1 Selection process of cases of GLP-1RA-associated hypoglycemia from the FAERS database. DEMO, demographic and administrative information; DRUG, drug information; FAERS, Food and Drug Administration’s Adverse Event Reporting System; GLP-1RA, glucagon-like peptide-1 receptor agonist; REAC, adverse event.CC BY-NC-ND · PubMed Central
Figure 2 Numbers and proportions of hypoglycemia cases after receiving GLP-1RAs in different years. GLP-1RA, glucagon-like peptide-1 receptor agonist.
Figure 2 Numbers and proportions of hypoglycemia cases after receiving GLP-1RAs in different years. GLP-1RA, glucagon-like peptide-1 receptor agonist.CC BY-NC-ND · PubMed Central
Figure 3 Time to event onset of hypoglycemia following different GLP1-RA regimens. GLP-1RA, glucagon-like peptide-1 receptor agonist.
Figure 3 Time to event onset of hypoglycemia following different GLP1-RA regimens. GLP-1RA, glucagon-like peptide-1 receptor agonist.CC BY-NC-ND · PubMed Central
Figure 4 The number of total reports, hospitalization proportions, and fatality proportions of GLP-1RA-associated hypoglycemia. GLP-1RA, glucagon-like peptide-1 receptor agonist.
Figure 4 The number of total reports, hospitalization proportions, and fatality proportions of GLP-1RA-associated hypoglycemia. GLP-1RA, glucagon-like peptide-1 receptor agonist.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 49

Metadata

Authors
Zhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Zhao, Bin
Venue
Annals of Translational Medicine
Published
2021-09
Volume
9
Issue
18
Pages
1482-1482
ISSN
  • 2305-5839 (ISSN-L)
  • 2305-5847
OpenAlex
W3201672265
Cited by
49
References
45
Citations by year
2026: 16 · 2025: 14 · 2024: 10 · 2023: 5 · 2022: 3 · 2021: 1
FWCI
3.10
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
receptor agonists, hypoglycemia, drug safety, lixisenatide, albiglutide, saxagliptin, liraglutide, dulaglutide, tirzepatide, adverse drug reactions, post-marketing surveillance, FDA Adverse Event Reporting System, disproportionality analysis, Bayesian analysis, time to onset, hospitalization, mortality, type 2 diabetes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. https://app.cochat.ai/papers/10.21037/atm-21-4162
The paper
Zhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B. (2021). Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Annals of Translational Medicine. https://doi.org/10.21037/atm-21-4162

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.